<DOC>
	<DOCNO>NCT00461708</DOCNO>
	<brief_summary>This single arm study evaluate relationship skin toxicity Tarceva combination gemcitabine , survival , patient advance and/or metastatic pancreatic cancer . All patient receive gemcitabine 100mg/m2 i.v . weekly ; Tarceva administer 100mg po per day . The anticipated time study treatment disease progression , target sample size 100-500 individual .</brief_summary>
	<brief_title>A Study Tarceva ( Erlotinib ) Combination With Gemcitabine Unresectable and/or Metastatic Cancer Pancreas : Relationship Between Skin Toxicity Survival</brief_title>
	<detailed_description />
	<mesh_term>Pancreatic Neoplasms</mesh_term>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Erlotinib Hydrochloride</mesh_term>
	<mesh_term>Pancrelipase</mesh_term>
	<criteria>adult patient , &gt; =18 year age ; locally advance and/or metastatic pancreatic cancer ( stage III IV ) ; Karnofsky performance Status &gt; =60 % . local ( stage IA IIB ) pancreatic cancer ; &lt; =6 month since last adjuvant chemotherapy ; previous systemic therapy metastatic pancreatic cancer ; primary tumor within last 5 year ( except adequately treated cancer situ cervix , basal cell skin cancer ) ; clinically significant cardiovascular disease .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2015</verification_date>
</DOC>